HRP20161344T1 - Novi citostatski 7-deazapurinski nukleozidi - Google Patents

Novi citostatski 7-deazapurinski nukleozidi Download PDF

Info

Publication number
HRP20161344T1
HRP20161344T1 HRP20161344TT HRP20161344T HRP20161344T1 HR P20161344 T1 HRP20161344 T1 HR P20161344T1 HR P20161344T T HRP20161344T T HR P20161344TT HR P20161344 T HRP20161344 T HR P20161344T HR P20161344 T1 HRP20161344 T1 HR P20161344T1
Authority
HR
Croatia
Prior art keywords
compound according
alkyl
halo
heteroaryl
hydrogen
Prior art date
Application number
HRP20161344TT
Other languages
English (en)
Croatian (hr)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of HRP20161344T1 publication Critical patent/HRP20161344T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00032—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries characterised by data exchange
    • H02J7/00036—Charger exchanging data with battery
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries
    • H02J7/00047—Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HRP20161344TT 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi HRP20161344T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18
PCT/CZ2009/000004 WO2009089804A1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides
EP09702842.7A EP2231689B1 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Publications (1)

Publication Number Publication Date
HRP20161344T1 true HRP20161344T1 (hr) 2016-11-18

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161344TT HRP20161344T1 (hr) 2008-01-18 2009-01-15 Novi citostatski 7-deazapurinski nukleozidi
HRP20181774TT HRP20181774T1 (hr) 2008-01-18 2018-10-29 Novi citostatski 7-deazapurinski nukleosidi

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20181774TT HRP20181774T1 (hr) 2008-01-18 2018-10-29 Novi citostatski 7-deazapurinski nukleosidi

Country Status (18)

Country Link
US (1) US8093226B2 (enExample)
EP (2) EP3133080B1 (enExample)
JP (2) JP5485172B2 (enExample)
CN (1) CN101977923B (enExample)
AU (1) AU2009204568B2 (enExample)
CA (1) CA2711384C (enExample)
CY (2) CY1118104T1 (enExample)
DK (2) DK3133080T3 (enExample)
ES (2) ES2693551T3 (enExample)
HR (2) HRP20161344T1 (enExample)
HU (2) HUE030767T2 (enExample)
LT (2) LT2231689T (enExample)
NZ (1) NZ586610A (enExample)
PL (2) PL3133080T3 (enExample)
PT (2) PT3133080T (enExample)
SI (2) SI3133080T1 (enExample)
TR (1) TR201815961T4 (enExample)
WO (1) WO2009089804A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55634B1 (sr) 2005-12-13 2017-06-30 Incyte Holdings Corp Heteroaril substituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HUE043732T2 (hu) 2007-06-13 2019-09-30 Incyte Holdings Corp Januskináz gátló hatású (R)-3-(4-(7H pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropánnitril sók alkalmazása
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
ES2437917T3 (es) * 2009-04-22 2014-01-15 Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. Nuevos nucleósidos de 7-desazapurina para usos terapéuticos
KR20120030447A (ko) 2009-05-22 2012-03-28 인사이트 코포레이션 Ｊａｋ 저해물질로서 ３-［４-（７ｈ-피롤로［２,３-ｄ］피리미딘-４-일）-１ｈ-피라졸-１-일］옥탄- 또는 헵탄-니트릴
EP2432555B1 (en) * 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI531572B (zh) 2010-03-10 2016-05-01 英塞特公司 作為ｊａｋ１抑制劑之哌啶－４－基三亞甲亞胺衍生物
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
CA2818389A1 (en) * 2010-11-18 2012-05-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
PH12013501001A1 (en) 2010-11-19 2019-09-02 Incyte Holdings Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CR20190073A (es) 2012-11-15 2019-04-25 Incyte Holdings Corp FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
SMT202100694T1 (it) 2013-03-06 2022-03-21 Incyte Holdings Corp Procedimenti e intermedi per produrre un inibitore di jak
CA2920108C (en) 2013-08-07 2022-07-05 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10414788B2 (en) 2016-06-29 2019-09-17 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
EP3746429B1 (en) 2018-01-30 2022-03-09 Incyte Corporation Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
TW202114708A (zh) * 2019-06-18 2021-04-16 日商大鵬藥品工業股份有限公司 具有吡咯并嘧啶骨架之新穎磷酸酯化合物或其藥學上可容許之鹽
CN115515593A (zh) * 2020-02-17 2022-12-23 勒芬天主教大学 作为药物的新的6-取代的7-脱氮嘌呤和相应的核苷
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (enExample) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
NZ546055A (en) * 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CA2584367A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
AR056327A1 (es) * 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales

Also Published As

Publication number Publication date
AU2009204568A1 (en) 2009-07-23
DK2231689T3 (en) 2016-09-19
LT3133080T (lt) 2018-11-12
CN101977923B (zh) 2014-10-08
EP3133080A1 (en) 2017-02-22
WO2009089804A1 (en) 2009-07-23
NZ586610A (en) 2012-08-31
AU2009204568B2 (en) 2013-10-03
PT3133080T (pt) 2018-11-16
US20090203637A1 (en) 2009-08-13
HUE030767T2 (en) 2017-05-29
HUE041598T2 (hu) 2019-05-28
SI2231689T1 (sl) 2016-11-30
PT2231689T (pt) 2016-10-07
SI3133080T1 (sl) 2018-12-31
US8093226B2 (en) 2012-01-10
JP2014058567A (ja) 2014-04-03
EP2231689A1 (en) 2010-09-29
JP5485172B2 (ja) 2014-05-07
CN101977923A (zh) 2011-02-16
PL2231689T3 (pl) 2017-01-31
CA2711384C (en) 2016-07-26
ES2598503T3 (es) 2017-01-27
CA2711384A1 (en) 2009-07-23
CY1121364T1 (el) 2020-05-29
CY1118104T1 (el) 2017-06-28
JP2011509949A (ja) 2011-03-31
TR201815961T4 (tr) 2018-11-21
EP3133080B1 (en) 2018-08-01
LT2231689T (lt) 2016-10-25
PL3133080T3 (pl) 2018-12-31
ES2693551T3 (es) 2018-12-12
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
EP2231689B1 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
HRP20161344T1 (hr) Novi citostatski 7-deazapurinski nukleozidi
HRP20210365T1 (hr) Dna-pk inhibitori
JP2011509949A5 (enExample)
CA2525214A1 (en) Macrocyclic quinazoline derivatives as antiproliferative agents
MX2009011997A (es) Derivados de pirrolopirimidin-7-ona y su uso como farmaceuticos.
WO2007048066A3 (en) Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
HRP20131021T1 (hr) Novi 7-deazapurin nukleozidi za terapijske uporabe
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
ME02423B (me) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
NZ598294A (en) Heterocyclic compounds for the inhibition of pask
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
IL276711B2 (en) Arginase inhibitors and methods of use thereof
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
ME02558B (me) Inhibitori replikacije virusa gripa
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
MY156552A (en) Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
IL296199B2 (en) Salt form of a human hi stone methyltransf erase ezh2 inhibitor
NZ629432A (en) Heterocyclyl compounds as mek inhibitors
MX2010003155A (es) Derivados de ciclopropil aril amida y uso de los mismos.
MY151986A (en) Adamantyl diamide derivatives and uses of same
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.